Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

NCT02309177 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms
Pancreatic Neoplasms

Interventions

DRUG: nab-Paclitaxel
DRUG: Nivolumab
DRUG: Gemcitabine
DRUG: Carboplatin

Sponsor

Celgene